Alkeon Capital Management Reduces $7M in Alto Neuroscience, Inc. ($ANRO)
Key Points
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Alkeon Capital Management reduced its position in Alto Neuroscience, Inc. ($ANRO) by 52.40% during the most recent quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 227,101 shares of Alto Neuroscience, Inc. after selling 250,000 shares during the quarter. Alkeon Capital Management's holdings in Alto Neuroscience, Inc. were worth $6.19 million as of its most recent filing.
Alto Neuroscience, Inc. Stock Down 22.5%
Shares of Alto Neuroscience, Inc. ($ANRO) traded around $27.23 on Saturday, down 22.5% for the day.
Alto Neuroscience, Inc. Earnings
Analysts Set New Price Targets
About Alto Neuroscience, Inc.
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
Get Alto Neuroscience, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ANRO, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.